Clinical Trial Update: Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the immunogenicity and safety of Takeda's tetravalent dengue vaccine candidate (TDV) in flavivirus-naïve and dengue-immune adults; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• TDV (tetravalent dengue vaccine candidate) (tetravalent dengue vaccine)

Snippet

Sponsor: Takeda | Conditions: Dengue Fever | Phase 2 | Status: COMPLETED | Results posted: 2024-04-10